Phase 3 N=88 Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole
Invasive Fungal Infections
Primary: Comparison of Plasma Itraconazole Levels and Hydroxyitraconazole Levels at Day 14 — 60.5; 71.0 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,538 Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Prostate Cancer
Primary: Percentage of Participants Alive (Overall Survival) — 90.0; 91.0 percentage of participants — p=0.22
Phase 3 N=539 Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia · Leukemia
Primary: Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia — 31.9; 15.1 months — p=0.0324
Phase 3 N=6 A Study Comparing Green Fluorescent Dye and Radioactive Dye for Sentinel Lymph Node Biopsy in Pediatric Cancers
Pediatric Patients With Solid Tumors
Primary: % of Patients in Whom a Sentinel Lymph Node is Identified
Phase 3 N=336 A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia
Schizophrenia
Primary: Number of Participants With Adverse Events (AEs) — 64; 74 Participants
Phase 3 N=1,001 A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma
Asthma
Primary: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Concentration Curve From 0 to 6 Hours (AUC0-6 Hours) Over 12 Weeks — 258.6; 242.2…
Phase 3 N=120 A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution
Anesthesia, Local
Primary: The Number of Patients Who Experienced Ocular Anesthesia Following Treatment of AG-920 Compared to Placebo at 5 Minutes — 41; 2 Participants
Phase 3 N=512 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC
Pancreatic Adenocarcinoma
Primary: Overall Survival (OS) — 7.5; 6.7 months
Phase 3 N=160 Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)
Neurodermatitis
Primary: Percentage of Participants With Greater Than or Equal to (>=) 4 Points Improvement (Reduction) From Baseline in Worst-Itch Numeric Rating Scale (WI-NRS) Scores at Week…
Phase 3 N=3,132 A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma
Asthma
Primary: Number of Participants With a Severe Asthma Exacerbation Event — 207; 266; 241; 276 Participants — p=<0.001
Phase 3 N=505 A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)
Non Small Cell Lung Cancer
Primary: Event-Free Survival (EFS) — 20.80; 31.57 Months — p=0.0052
Phase 3 N=172 Vitamin D Supplementation in Multiple Sclerosis
Relapsing Remitting Multiple Sclerosis
Primary: Proportion of Subjects That Experience a Relapse — 0.32; 0.34 proportion of participants — p=0.60
Phase 3 N=30 Sodium Pyruvate Nasal Spray Treatment of COVID-19 Infection
COVID-19
Primary: Evaluate the Ability of Inhaled Nasal Sodium Pyruvate to Change COVID-19 Viral Titers. — 5.61; 6.57; 4.67; 5.86 Log10 viral RNA copies — p=0.0197
Phase 3 N=683 Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)
Depressive Disorder, Major
Primary: Change From Baseline in Children Depression Rating Scale - Revised (CDRS-R) Total Score at Week 8 of Phase B — -17.48; -19.20; -19.94; -20.78 units on a scale — p=0.0937
Phase 3 N=106 Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis
Atopic Dermatitis
Primary: Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16 — 17; 14 Participants